Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Endo (ENDP) downgraded to Neutral at Piper Jaffray by analyst David Amsellem, who said it will be difficult for Endo to make much of a dent in its net debt over the next two years amid significant pressure on its generics segment. The analyst adds that it is not clear that Endo is positioned to return to earnings growth in 2017 following management's comments on the earnings call. Endo was also downgraded at Leerink, RBC Capital and Mizuho due to the company's lowered business outlook and a lack of conviction that management can turnaround the business in a timely fashion. 2. Zoetis (ZTS) downgraded to Sell at Goldman with analyst Jami Rubin saying the company's fundamentals are sound, but peers offer more share upside. 3. Michaels (MIK) downgraded to Neutral at Goldman citing valuation following the recent rally in the shares. 4. Square (SQ) downgraded to Underperform at Wedbush by analyst Gil Luria based on expectations growth will decelerate over the next couple years due to intensified competition from PayPal (PYPL). Luria believes Square is close to saturation and sees early signs in the lack of merchant count growth over the last few quarters and said margins are increasingly capped. 5. Weatherford (WFT) downgraded to Market Perform at Wells Fargo with analyst Judson Bailey citing "significantly greater concern" about the company's liquidity position. The analyst sees a "significantly lower" cash flow outlook for Weatherford through 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.